The first needle-free emergency treatment for anaphylaxis – in the form of a nasal spray – will now be available in the UK.

The MHRA has approved a nasal spray adrenaline formulation that offers the first needle-free alternative for the emergency treatment of anaphylaxis.

The first needle-free emergency treatment for anaphylaxis - in the form of a nasal spray - will now be available in the UK.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the adrenaline (epinephrine) nasal spray (EURneffy), the first needle-free emergency treatment for anaphylaxis.

UK medicines regulators have approved an adrenaline nasal spray to treat anaphylaxis. The needle-free option can be used in adults and children weighing over 30kg, the Medicines and Healthcare ...

Key Takeaways An insulin nasal spray might be a potential treatment for Alzheimer’s diseaseBrain scans show insulin travels to 11 key brain regions associated with memory and thoughtPeople with ...

A groundbreaking brain imaging study from Wake Forest University School of Medicine confirms a vital step toward new Alzheimer's disease treatments: Intranasal insulin, delivered via a simple ...

The 16-person, first-in-human study showed promising safety and efficacy data for delivering insulin intranasally in older adults.

Using a novel radiotracer, [68Ga]Ga-NOTA-insulin, delivered with a specialized six-spray nasal system, participants underwent a 40-minute brain PET scan followed by whole-body imaging.

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) ...

Concurrent with the FDA acceptance, Milestone is also announcing today the extension of its $75.0 million purchase and sale agreement (Royalty Purchase Agreement) with existing shareholder, RTW ...

About neffy® neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in adults and children aged 4 years and older who weigh 33 lbs. or greater.